ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Emgality (galcanezumab) by Year
Emgality (galcanezumab) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly Emgality (galcanezumab): 28.0% in FY2024, up 24.0 pts from a year earlier. No newer figure appears in the documents we track.
Latest, FY2024
28.0%
Period ended Dec 31, 2024
Change on a year earlier
+24.0 pts
4.0% in FY2023
History
4 years
Since FY2021
Sources
4
Documents cited below
Where the FY2024 figure comes from
“|| Emgality | 559.7 | 310.7 | 870.4 | 678.3 | 28”
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Emgality (galcanezumab) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 28.0% | +24.0 pts | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 4.0% | -9.0 pts | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 13.0% | -46.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 59.0% | – | Form 10-K FY2021 (filed 2022-02-23) ↗ |
Cite this data
StockData. (2026). Eli Lilly Emgality (galcanezumab) (%), annual FY2021–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-emgality-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.